<?xml version="1.0"?>
<Articles JournalTitle="Acta Medica Iranica">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Acta Medica Iranica</JournalTitle>
      <Issn>0044-6025</Issn>
      <Volume>59</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="epublish">
        <Year>2021</Year>
        <Month>07</Month>
        <Day>05</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Is Down Syndrome Related to Pulmonary Arterial Hypertension? A Comparative Study</title>
    <FirstPage>280</FirstPage>
    <LastPage>284</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Ghazaleh</FirstName>
        <LastName>Doostparast Torshizi</LastName>
        <affiliation locale="en_US">Department of Pediatrics, Division of Environmental Pediatrics, NYU Langone Medical Center, New York, NY, USA. AND  Department of Pediatrics, Hakim Hospital, Neyshabur University of Medical Sciences, Neyshabur, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Mahboobe</FirstName>
        <LastName>Gholami</LastName>
        <affiliation locale="en_US">Department of Midwifery, Hakim Hospital, Neyshabur University of Medical Sciences, Neyshabur, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Behzad</FirstName>
        <LastName>Alizadeh</LastName>
        <affiliation locale="en_US">Department of Pediatrics Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2020</Year>
        <Month>06</Month>
        <Day>24</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>04</Month>
        <Day>16</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Down syndrome (DS) is a genetic impairment associated with comorbidities such as Congenital Heart Disease (CHD). Pulmonary Arterial Hypertension (PAH) is a complication of CHD in most patients. Due to insufficient documents about the prevalence of PAH in DS with CHDs compared to non-DS (NDS)+CHD patients, this study aimed to compare the prevalence of PAH between DS-CHD and NDS-CHD patients. This is a cross-sectional study conducted on DS-CHD patients referred to the Pediatric and Congenital Cardiology Division at Imam Reza training hospital in Mashhad, Iran, between April 2015 and February 2016. The comparison group included NDS-CHD children matched in terms of age and gender. A comprehensive Echocardiography was run for all patients to determine the types of CHD and pulmonary arterial pressure. Seventy-seven patients were enrolled in the study (47 in the DS-CHD group and 30 in the NDS-CHD group). 48.9% of the DS-CHD patients and 23.3% of the NDS-CHD group developed PAH, which revealed a significantly higher rate of PH among DS-CHD patients (P=0.025). Our findings denote a higher prevalence of PAH among DS-CHD patients compared to NDS-CHD patients. Such an observation is a meaningful warning for DS patients to take early necessary medical or corrective therapies for CHD in order to prevent complications and irreversible pulmonary vascular disease.</abstract>
    <web_url>https://acta.tums.ac.ir/index.php/acta/article/view/8575</web_url>
  </Article>
</Articles>
